CGTLive’s Weekly Rewind – December 15, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Gene-Edited Cell Therapy Improves Sickle Cell, Transfusion-Dependent Thalassemia Phenotypes

Rabi Hanna, MD, presented updated data from the RUBY and EdiThal trials at ASH 2023.

2. Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple Myeloma

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

3. Obe-cel Shows Complete Remissions up to 3 Years in R/R B-ALL

A pooled analysis of the ALLCAR19 and FELIX trials including patients with R/R B-ALL, B-CLL, and B-NHL were presented at ASH 2023.

4. Gregory W. Roloff, MD, on Assessing Real-World Experience of Brexu-Cel in Adults With B-ALL

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

5. Patient Reported Outcomes May Help Give a Better Picture of Exa-cel's Impact

Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital discussed PRO data on Vertex and CRISPR’s gene-edited cell therapy for sickle cell disease.